Michael Gibney
Senior Editor & WriterMichael Gibney is a senior writer and editor for PharmaVoice. Before that, he covered the pharmaceutical industry as a healthcare reporter for three and a half years at S&P Global Market Intelligence and served as an editor at FiercePharma and FierceBiotech. Besides industry reporting, Michael has also covered science, wildlife and environmental issues as well as local news in Connecticut and Montana. A graduate of Bucknell University and the University of Missouri Journalism School, he is based in the Washington, D.C., area where you’ll find him hiking with two retired racing greyhounds, finding local breweries and grilling in the backyard.
59 articles by Michael Gibney
-
Execs at Pfizer, Novartis, Amgen and GSK tackle shifting priorities — reflecting the state of Big Pharma
Feb. 2, 2023 -
This biotech CEO secured two billion-dollar Big Pharma deals during the pandemic
Jan. 31, 2023 -
Economic crisis? J&J execs say that won’t stop them from hitting $60B target
Jan. 25, 2023 -
AstraZeneca’s newest asthma launch fills a gap as generics chip away at respiratory flagships
Jan. 24, 2023 -
A Moderna tie-up ushers in new era for CytomX
Jan. 18, 2023 -
Biopharma M&A may get the push it needs in 2023, but with a face lift
Jan. 12, 2023 -
Chinook Therapeutics nears the finish line in kidney disease
Jan. 10, 2023 -
Lilly, Biogen, Eisai brace for Alzheimer’s boom or bust in 2023
Jan. 5, 2023 -
Beer, dolphins and more discoveries that could shed light on Alzheimer’s disease
Dec. 22, 2022 -
Blood cancer cures aren’t here yet — but incremental combinations bring the field closer
Dec. 19, 2022 -
At the heart of hematology breakthroughs, a community of researchers and patients comes together
Dec. 13, 2022 -
For Duchenne-focused Sarepta, gene therapy is the natural next step
Dec. 8, 2022 -
5 final FDA action dates to watch this year
Dec. 1, 2022 -
Evommune’s unique method of drug discovery is more than skin deep
Nov. 29, 2022 -
Why the biopharma ‘IPO playbook’ changed in 2022
Nov. 21, 2022 -
Is AI just hype or a real revolution in pharma? It’s complicated
Nov. 17, 2022 -
To explore cancer’s genetic mysteries, researchers turn to ‘MACHETE’
Nov. 16, 2022 -
3 ways pharma can weather a recession
Nov. 10, 2022 -
While CAR-T wait times remain ‘heartbreaking,’ researchers push for innovations that could help
Nov. 8, 2022 -
‘Zombie’ cells, Shkreli and cats — new research in toxoplasmosis and how the three are connected
Nov. 3, 2022 -
While DCTs get all the hype, some industry insiders say the future is a digital hybrid
Nov. 1, 2022 -
Riches, rags, riches: Is Biogen the Cinderella of biotechs?
Oct. 27, 2022 -
Biosimilars will gain ground in 2023 with Humira launches — and that’s just the beginning
Oct. 24, 2022 -
J&J reveals just how much economic turbulence is affecting Big Pharma
Oct. 20, 2022 -
He helped discover BMS’s psoriasis pill Sotyktu. Here’s what he has to say about early science in Big Pharma
Oct. 17, 2022